1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Physician Views: Post ADA view on key diabetes market developments

  • July 2013
  • Firstword Pharma
Report ID: 1543882

Summary

Table of Contents

Last week’s American Diabetes Association (ADA) meeting provided further evidence that the diabetes market is likely to be the pharmaceutical industry’s most competitive disease area over the next decade.

With regards to oral therapies, positive data for Eli Lilly’s dulaglutide has spurred the view among analysts that the GLP-1 agonist market will grow substantially, while players who already market products within this class – Novo Nordisk and AstraZeneca/Bristol-Myers Squibb – will also be looking at ways to accelerate revenue growth.

Similarly, forecasts for the SGLT-2 inhibitor market appear to be steadily moving upwards, driven primarily by a strong uptake for Johnson & Johnson’s Invokana.

Previous FirstWord Physician Views polls have indicated that recent FDA concern surrounding the safety of DPP-IV inhibitor products has had a minimal impact on prescribing trends among endocrinologists – a trend that is likely to solidify in light of the FDA indicating that only long term outcome studies can demonstrate if there is a significant pancreatic safety signal.

Attention has thus shifted to outcome studies, but in the short to medium term with regard to the possibility of demonstrating cardiovascular benefit versus placebo. The first of these studies read out two weeks ago – for AstraZeneca and Bristol-Myers Squibb’s Onglyza – and demonstrated non-superiority. Whilst this was widely expected, analysts have also expressed some disappointment given that sales growth for the DPP-IV class has slowed in recent months.

In the long acting insulin market, FDA rejection of Novo Nordisk’s Tresiba in February was a clear disappointment, although Sanofi looks poised to take advantage via its efforts to extend and enhance its market-leading Lantus franchise. At the ADA meeting, Sanofi released the first Phase III data for its next-generation Lantus programme (known as Lantus U300) designed to provide greater benefit in terms of reducing hypoglycaemic events. Analysts suggest this is the first evidence to realistically demonstrate that continued growth for Lantus past its patent expiry date is feasible.

Reasons to Buy this Report

In light of recent developments, this week’s Physician Views poll will ask US-based endocrinologists:

• Whether they anticipate data from the SAVOR outcomes study will impact their prescribing habits with regard to AstraZeneca and Bristol-Myers Squibb’s Onglyza
• To what percentage of GLP-1 patients they would prescribe Eli Lilly’s dulaglutide if it was available today
• By what percentage they would expect to increase their usage of AstraZeneca and Bristol-Myers Squibb’s GLP-1 agonist Bydureon if it was administered in a more convenient pen device?
• What the current level of unmet need is for novel longer acting insulins that are able to reduce the rate of hypoglycaemia
• Where they believe they are most likely to use SGLT-2 inhibitors within the treatment paradigm

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Needle-Free Diabetes Management Market Size, Share, Development, Growth and Demand Forecast to 2025 - Industry Insights by Device Type

  • $ 5100
  • Industry report
  • February 2017
  • by P&S Market Research

Market Overview Needle-free diabetes management refers to treatment, diagnosis and monitoring of diabetic patients without using needles. Needle-free diabetes management devices are used for injecting ...

Future of Diabetes Care Paradigms, Forecast to 2022

  • $ 4950
  • Industry report
  • March 2017
  • by Frost & Sullivan

Innovations to Disrupt Diabetes Wellness, Diagnosis, Monitoring, and Therapy Diabetes management is on the verge of being disrupted by innovative technologies such as artificial pancreas, non-invasive ...

Opportunity in the Indian Anti-Diabetic Pharmaceuticals Market - 2017

  • $ 4500
  • Industry report
  • March 2017
  • by Feedback Business Consulting

This report provides insight into the current market scenario, structure and practices. In depth market scenario includes: - Current market size estimate - Revenues by players - Top 5 Companies - Market ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.